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Background: A prospective, non-randomised, transversal and comparative study, carried out in INOVA Vision
Institute and Autonomous University of Aguascalientes. Pterygium is an important illness that affects 22% people
from tropic and equatorial zones. Is an inflammatory process caused by UV rays, and it has a behavior similar to a
neoplasm. For this study was taken into consideration 191 samples from the INOVA Vision Institute, Aguascalientes,
Mexico. Include 73 pterygia samples, which were obtained during resection under sterile conditions. 44 normal
conjunctiva samples were obtained from the same patients when harvesting the conjunctival autograft, or from
other patients undergoing extracapsular cataract extraction from the superior bulbar region. Tears from patients
with pterygium (n = 50) and normal volunteers (n = 24) were obtained using a calibrated glass micro capillary tube.
The surgical conjunctiva and pterygia samples were subjected to reverse-transcription polymerase chain reaction
(RT-PCR), western blot, and immunohistochemistry. Tears were analyzed by enzyme-linked immunosorbent assays.
Methods: This was a prospective, non-randomised study involving 191 biological samples taken from patients with
pterygium and normal volunteers, whom were operated under local anaesthesia by either complete resection of
the lesion with primary closure, or resection with conjunctival autograft. Tissue samples were fixed in 10%
formaldehyde. Sections were routinely stained with hematoxylin and eosin. HCC expression was evaluated by
reverse-transcription polymerase chain reaction (RT-PCR), immunohistochemistry, and by western blotting. All tears
samples were analyzed by enzyme-linked immunosorbent assays (ELISA).
Results: Expression levels and distribution patterns of HCC in normal conjunctiva and pterygium. Higher levels of
HCC mRNAs and proteins were detected in pterygium compared with a normal conjunctiva. Immunohistochemistry
revealed that HCC was localized in the apical cells of the epithelium in the normal conjunctiva. In contrast, HCC
was detected in all extension of epithelial tissue, from apical to basal cells in pterygia. The concentration of HCC
protein in tears was higher in patients with pterygium versus controls.
Conclusion: HCC may play an important role in protecting normal conjunctiva, and regulating inflammatory
conditions of the anterior ocular surface.
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A pterygium is a fibrovascular lesion of the ocular sur-
face that can display aggressive clinical behavior and oc-
casionally threaten vision [1]. The lesion consists of an
initial disruption of the corneal-conjunctival barrier,
characterized by extensive cell proliferation, inflamma-
tion and connective tissue remodeling, from the limbus
to the central cornea [2]. Epidemiological data support
that chronic exposure to UV light has a prominent role
in the pathogenesis of pterygium that affect 22% people
from tropic and equatorial zones [3]. Girolamo et al.,
established the role of matrix metalloproteinases
(MMPs) and their inhibitors in the degradation of extra-
cellular matrix (ECM) components (proteoglycans,
glycoproteins and collagen, I and III) in pterygium. They
suggested that inhibitors of MMP-1 and MMP-3 have a
protective role against ECM degradation [4]. Defects in
biological mechanisms controlling protease activities can
have numerous effects, such as neurodegeneration, car-
diovascular diseases, osteoporosis, arthritis, and metasta-
ses of cancers [5]. These pathological entities are
activated by chronic inflammation, angiogenesis and tis-
sue proliferation, all of which occur in pterygium.
Cystatins have been identified as proteins with a particu-
lar sequence motif that form equimolar, tight and revers-
ible bonds with cysteine peptidase. These cystatins
represent a group of potent, non-covalent, competitive
inhibitors of mammalian lysosomal cysteine proteinases
that have been conserved throughout evolution.
Cystatins inhibit cysteine proteinases belonging to the
C1 superfamily, including plant papain and the mamma-
lian cathepsins B, C, H, K, L, and S [6]. An important
member of this protein family is human cystatin C
(HCC), a non-glycosylated and low molecular weight (14
kDa) protein that is present in almost all human fluids,
including tears [7]. HCC has not been studied exten-
sively in ophthalmic pathologies. Paraoan et al.,
discovered a possible role for cystatin in the neuroepi-
thelium during macular degeneration in human eyes;
they also studied other structures of the eye (iris, ciliary
body, lens epithelium and ciliary body epithelium) using
immunohistochemical methods [8]. Another study
showed that the level of cystatin C in tears made up 10%
of the total protein content [9]. To date, there are no
studies regarding the presence of cystatin C in the
pterygium of human eyes. The objective of our study
was to determine the expression levels of HCC in
patients with pterygium.
Methods
This was a prospective, non-randomised study involving
191 biological samples taken from patients with
pterygium and normal volunteers. HCC expression was
evaluated using several techniques. Written informedconsent was obtained for each patient. Biological
samples were taken during surgery (pterygia and con-
junctivas) or consultation (tears) from the anterior
segment department of INOVA Vision Institute, Aguas-
calientes, Mexico. All experiments were carried out in
accordance with the Helsinki Declaration and approved
by the medical ethics committee of the INOVA Vision
Institute. 52 surgical of primary pterygia samples from
persons its age ranging between 55 to 65 years old (me-
dian age 55.21 ± 10 years), the 21 recurrent pterygia
samples were obtained from persons which ages ranging
between 58 to 63 years old (median age 65.12 ± 14 years
old), the samples were obtained during resection under
sterile conditions. 44 normal conjunctiva samples from
persons which ages ranging between 52 to 68 years old
(median age 62.57 ±6 years) the conjunctivas were
obtained from the same patients when conjunctival
autografts were harvested, or from other patients under-
going extracapsular cataract extraction from the superior
bulbar region. Tears from 50 patients with pterygium
and 24 normal volunteers who ages ranging between 51
to 67 years old (median age 61.31 ±9 years) were
obtained using a calibrated glass micro capillary tube.
One-third of tissue samples (pterygia and conjunctivas)
were analyzed by reverse-transcription polymerase chain
reaction (RT-PCR), one-third by immunohistochemistry,
and the remainder by western blotting. All tears samples
were analyzed by enzyme-linked immunosorbent assays
(ELISA).Surgical approach
Patients with pterygium were operated under local an-
aesthesia by either complete resection of the lesion with
primary closure, or resection with conjunctival autograft
[10]. The pterygium head was removed, using a sharp
blade, from the anterior corneal surface. The remainder
of the body tissue was dissected in a subconjunctival
plane. All pterygia were taken from the nasal region, ex-
cept for one pterygium of temporal origin. Normal con-
junctiva samples were taken from the superior bulbar
region when dissecting the conjunctival autograft, or
from the same region from patients who underwent
extracapsular cataract extraction.Tear sample collection
Patients were evaluated with a slit lamp to exclude any
disease of the anterior segment. Tear samples were
collected using a 5-μl calibrated glass micro capillary
tube (Blauband intra MARK, Brand GMBH, Werthein,
Germany) without touching the eye or eyelids. Samples
were taken at different times of the day to avoid diurnal
variations [11]. One sample typically contained 50 μl.
After collection, samples were centrifuged at 14,000 × g
Figure 1 (A) Morphological approach used to select the
optimal field of view to quantify HCC in surgical tissue
samples; the continuous lines' squares represent epithelial
fields quantified. (B) Example of an area of pterygium chosen for
the HCC quantifying.
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Pterygia and normal conjunctivas were fixed in 10% for-
maldehyde. Sections were routinely stained with
hematoxylin and eosin [12]. Each section (5-μm thick-
ness) was incubated with the appropriate primary anti-
body for 24 h in a humidified chamber at 4°C. The
primary antibody was polyclonal rabbit anti-HCC
(diluted 1:100; Ab7653, Abcam). Antibody was diluted
in phosphate-buffered saline (PBS) containing 0.2% (v/v)
Triton X-100 and 3% (w/v) bovine serum albumin
(BSA). Sections were washed, and then incubated with
goat anti-rabbit conjugated to horseradish peroxidase
enzyme (1:100; AP132, Serotec, AP132) in a humidified
chamber for 2 h at room temperature. Sections were
developed with diaminobenzidine (Sigma) until brown-
ish staining was evident.
Digital morphometry
We used an Axioscop 40 (Carl Zeiss) light microscope
equipped with a digital image acquisition system. For
each sample examined, 10 randomly chosen fields from
epithelial tissue represented by continuous lines squares
in Figure 1A were analyzed. HCC area was defined as
the ratio of an epithelium per unit of tissue as showed in
Figure 1B. Image Pro Plus software (Media Cybernetics,
Silver Spring, MD) was used to measure epithelial areas
[13,14].
RNA extraction and cDNA synthesis
RNA was extracted from individual pterygium samples
and pooled normal conjunctivas. RNA was extracted
from 5 mg of tissue using a total RNA Isolation System
(Promega, Madison, WI) according to the manu-
facturer’s instructions. Purity and quality of RNA were
assessed with the Nanodrop 1000 system (Thermo Sci-
entific, Wilmington, DE). We obtained 90 ± 10 ng of
RNA for each pterygium, and 100 ± 10 ng of RNA for
pooled conjunctiva samples. Synthesis of cDNA was
conducted using SuperScript™ first strand synthesis for
RT-PCR (Invitrogen, Groningen, The Netherlands) at
55°C for 45 min. Primers for the PCR were designed
using DNAstar 4.02 software. Primer sequences were 50-
GCG GCG TGC ACT GGA CTT TG-30 (HCC primer
forward) and 50-GCC GCC TGC TGC CTT CTC TG-30
(HCC primer reverse). The PCR consisted of 1 μl of
cDNA, 1.5 mM MgCl2, 0.2 mM dNTP, 0.5 μM each pri-
mer and 2.5 U of Taq DNA polymerase. Thermal cycling
involved a denaturing step at 94°C for 5 min, followed
by 25 cycles of denaturation (94°C, 5 min) and annealing
(61°C, 1 min), then a final extension step at 72°C for 2min. All reactions were performed in duplicate.
Amplicons were visualized by electrophoresis on 1.5%
(w/v) agarose gels stained with ethidium bromide.
ELISA
Of the 74 tear samples we analyzed, 28 were from
patients with primary pterygium; 22 were from recurrent
pterygium, and 24 were from a normal conjunctiva. In
the wells of a 96-well plate, 50 μl of a tear sample was
added to 50 μl of carbonate/bicarbonate buffer (pH 10)
to coat each well. Plates were incubated at 4°C over-
night. We added 0.1% (w/v) BSA in PBS (pH 7.4) to each
well for 45 min at 37°C, then performed three 5-min
washes with PBS containing 0.05% (v/v) Tween-20 (PBS-
Tw). Rabbit anti-HCC (diluted 1:1000 in PBS-Tw) was
added to wells and incubated for 1.5 h at 37°C. Wells
were washed with PBS-Tw, and then incubated with
goat anti-rabbit IgG conjugated to horseradish peroxid-
ase (diluted 1:2500 in PBS-Tw) for 1 h at room
temperature. Wells were again washed with PBS-Tw,
and ortho phenylenediamine added for color
Figure 2 (A) Using primers specific for HCC, a 550 bp amplicon
was amplified in conjunctiva, active recurrent pterygium, and
active primary pterygium (lanes 1, 2 and 3 respectively)
samples. (B) A portion of the constitutive B-globin gene was
amplified by RT-PCR (150 bp) in conjunctiva, active recurrent
pterygium, and active primary pterygium (lanes 1, 2 and 3
respectively) samples.
Barba-Gallardo et al. BMC Ophthalmology 2013, 13:6 Page 4 of 8
http://www.biomedcentral.com/1471-2415/13/6development. Absorbance values for each well were
determined at 490 nm in a iMark (Bio Rad) spectropho-
tometer [15].
Protein extraction
Frozen tissue sections from pterygium and conjunctiva
were placed in a glass tissue macerator (Kontes 15 ml)
with lysis buffer (10 mM Tris–HCl pH 7.4, 50 mM
NaCl, 3 mM iodoacetamide, three Mm (3S)-1-chloro-3-
tosylamido-7-amino-2-heptanone hydrochloride TLCK
and 1 mM phenylmethylsulfonyl fluoride PMSF). The
proportion of tissue to lysis buffer was 1 g/ml. Tissues
were lysed with 100 strokes, and samples kept on ice;
however, it was necessary to centrifuge samples at
15,000 rpm for 10 min at 4°C as they became dense. We
obtained two phases: the bottom phase corresponded to
membrane contents, and the supernatant contained the
contents of the cytosol. These phases were stored at
−20°C until required. We subjected human serum to an
LC10 column (Beckman Coulter Inc., Fullerton, CA)
according to the manufacturer’s instructions. Briefly, 100
μL of serum was diluted 5-fold with buffer A and
injected onto the column in buffer A at a flow rate of
0.5 ml/min for 25 min, then 2.0 ml/min for 5 min on a
Shimadzu LC10A VP system (Shimadzu Co., Kyoto,
Japan). After collection of the flow-through fraction
containing unbound proteins, the column was washed
and bound proteins were eluted with buffer B (stripping
buffer) at a flow rate of 2.0 ml/min for 18 min. Fractions
were collected into 1.5 ml micro centrifuge tubes.
Quantitation of proteins
A standard curve was constructed using BSA (range 0–1
mg/ml). Samples (1 μl of membrane or cytosol contents)
were added to 1 ml of Bradford's solution [16]. The ab-
sorbance of samples was determined at 595 nm.
Immunoblot analysis
A positive control was taken from the serum patients
with chronic renal failure. Pterygia and conjunctiva
tissues containing 100 μg of protein were mixed with an
equal volume of buffer and then boiled for 5 min.
Samples from human serum were dissolved in 15 μl of
sample preparation buffer, mixed well, and subjected to
sodium dodecyl sulfate (SDS) polyacrylamide gel electro-
phoresis according to Laemmli protocol [17]. Samples
were loaded onto a 7.5% separating gel, electropho-
resed and transferred to a nitrocellulose membrane.
Membranes were cut into strips and immersed in a
blocking reagent (10% skim milk in 50 mM Tris–HCl
pH 7.4 and 200 mM NaCl). The blocking reagent was
removed and rabbit anti-HCC (diluted 1:1000 in
blocking buffer) was added and incubated for 3 h at
37°C. After washing, peroxidase-conjugated anti-rabbitIgG antibody (diluted 1:1000 in blocking buffer) was
added and incubated for 2 h at 37°C. Reactions were
developed using a substrate solution (H2O2 containing
3.6 mM 4-chloro-1-naphthol).
Results
RT-PCR detection of HCC
Differential expression of HCC was observed, with an
over expression in recurrent and primary pterygia
compared with a normal conjunctiva (Figure 2B).
Morphological characteristics of conjunctiva and
pterygium
In the healthy conjunctiva, we observed non-keratinized
stratified squamous epithelium with four to eight layers
of cells (Figure 3A). These tissues had a well-defined
basement membrane that separated the underlying con-
nective tissue (CT) containing blood vessels (V) and
other normal cells of the connective tissue. Inflamma-
tory infiltrates were absent from normal tissue, and they
contained an orderly arrangement of collagen fibers
(Figure 3A). This contrasts with the pterygia tissue
samples which had thickened epithelial areas of 10 or
more layers (TE in Figure 3B), goblet cells (arrow in
Figure 3B) concentrated in the crypts of Henle, and a
well-defined basal lamina (double arrow in Figure 3B).
The underlying connective tissue (CT) presents an
increased number of cells, and other areas were
characterized by increased density of collagen. Addition-
ally, in areas close to blood vessels, infiltrates were rarely
observed (Figure 3B).
HCC immunohistochemistry
In the normal conjunctiva, we detected HCC in most
apical epithelial cells (arrow in Figure 4A) meantime,
other epithelial cells were negative for presence of HCC
(double arrow in Figure 4A). In primary pterygium
(Figure 4B), we observed HCC faintly in all areas of
the thickened epithelium (key in Figure 4B) with
Figure 3 (A) A healthy conjunctiva lacking evidence of inflammatory cell infiltration, containing few vessels (V), normal epithelium
(arrows), and uniform connective tissue (CT). (B) Primary Pterygium. Thickened epithelium (TE), epithelial goblet cells (arrow), and basal lamina
(double arrow), on its right, we identified connective tissue (CT) (400× Magnification).
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cells. We detected solid expression of HCC in the epi-
thelium of recurrent pterygium (key in Figure 4C) in
cells from the basal, middle and apical layers, and we
could quantify by morphometry (Figure 1A). HCC was
not observed in CT cells.
Digital morphometric analysis
From the images that we obtained we saw that samples
in the pterygia groups contained larger positive areas in
terms of distribution regarding the conjunctiva
(Figure 5). We compared data sets for three cases using
an unpaired Student’s t-test. The mean of the area in theFigure 4 (A) Superficial epithelial cells in the healthy
conjunctiva were positive for the presence of HCC (arrow).
(B) Most of the epithelial tissue was positive for HCC in primary
pterygium (key). (C) Nearly all the epithelial tissue was positive for
HCC in recurrent pterygium (key; 400× Magnification).primary pterygia and the conjunctiva showed significant
differences between groups (p < 0.0001). A comparison
of recurrent pterygia and normal conjunctivas, or of pri-
mary and recurrent pterygia, indicated no significance.Western immunoblot detection of HCC
HCC expression levels were increased in active primary
and active recurrent pterygia (Figure 6) as determined
by western immunoblotting. Expression levels of HCC
were lower in the conjunctiva compared with the
pterygia samples (Figure 6A). The protein that we
detected corresponded to a 14 kDa, as described in the
literature. Taken into consideration of the house keeping
alfa actin expression, we detected that the presence of
HCC in recurrent pterygium was highest as to the posi-
tive control, secondly was primary pterygium, finally theFigure 5 Quantitation of reactivity to HCC antibody in
conjunctivas, primary pterygia and recurrent pterygia. HCC
levels in conjunctivas were lower compared with those in primary
and recurrent pterygia (p < 0.0001). The area of reactivity between
primary and recurrent pterygia was not significantly different.
Figure 6 Detection of HCC. A) Immunoblot. Lane 1, molecular
weight markers; 2, serum of chronic renal failure sample (positive
control); 3, primary pterygium; 4, recurrent pterygium; 5 and 6,
healthy conjunctiva. Molecular Weight Human Cystatin C 17 kDa;
α actin 45 kDa. B) Density analysis of immuno localized protein HCC
in Western blot, we observed height density in Recurrent pterygium
as in positive control.
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samples (Figure 6B).
ELISA detection of HCC in tear samples
Our analysis showed that HCC molecules were present
in the tear film of all patients and controls. In healthy
people, the concentration of HCC was lower (0.05 UA ±
0.0003) than in patients with pterygium (0.13 UA ± 0.02;
Figure 7); and this difference was statistically significantFigure 7 Quantitation of HCC by ELISA in tears from active
recurrent pterygium, active primary pterygium and healthy
individuals. Absorbance values were increased in recurrent pterygia
compared with primary pterygia. The amount of HCC in the tears of
patients with active recurrent pterygium was 33% higher than that
in healthy subjects.(P < 0.0002). We saw a higher concentration of HCC in
the tear film of patients with recurrent pterygium (0.19
UA ± 0.03) compared to patients who had primary
pterygium (0.10 UA; P < 0.0003). Sub-analysis of patients
with pterygium showed that patients with the active dis-
ease had higher concentrations of HCC than those with
inactive disease, for either the primary (0.12 vs. 0.08 UA)
or recurrent (0.18 vs. 0.15) scenarios (P < 0.04; Figure 7
and Table 1).
Discussion
Our study involved tissue samples (pterygium and con-
junctiva) obtained from surgery, and tears from patients,
with and without pterygium. All patients who underwent
surgery had active pterygium. Conversely, outpatients
with pterygium were classified as active if they presented
with vascularization, edema and active hyperaemia, or as
inactive if they showed a fibrotic component. Using RT-
PCR we found that HCC was expressed in both normal
conjunctiva and pterygium, supporting the findings of
Chang et al., who found HCC in another mucosa [11].
Abrahamson et al., found HCC in several autopsy tissue
specimens (heart, kidney, lung, liver, uterus and seminal
vesicles) and in several fluids (tears, saliva, cerebrospinal
fluid and seminal plasma) [18]. Wasselius et al., studied
cystatin C in the anterior segment of rat and mouse eyes
and found that expression of the protein was localized
to the ciliary body, cornea and retina [19]. In that study,
cystatin C was not detected in rat and mouse conjunc-
tiva. Our results presented here contradict those
presented by Wasselius et al.; this may be because of the
anatomical and histological variations between rodent
and human eyes. Other authors have noted that HCC
plays an important role in the regulation of proteolysis
and inflammatory diseases, controlling the activity of
cathepsin B in tissues and fluids, including tears [20].
Using immunohistochemistry, we found that normal
conjunctiva contained HCC in the most superficial epi-
thelial layers. In contrast, HCC was expressed in all epi-
thelial tissues of pterygia, from basal epithelial cells to
the most superficial layer of the epithelium. It is
interesting to note that this compartment has a high
proliferatives rate in comparison with a normal conjunc-
tiva, such as morphological changes we observed in a
picture from two tissues stained with H&E technique
(Figures 3A and B). Other authors have studied HCC
by immunohistochemistry but in different tissues.
Chang et al., showed light immunostaining intensity
corresponding to the presence of HCC in normal sinus
mucosa, and intense staining in an inflamed sinus mu-
cosa [11]. Based on the anti-inflammatory function(s) of
HCC, Chang et al., suggest that this protein may play an
important role in the protection of normal sinus mu-
cosa, and also in the prevention of aggravation of
Table 1 Comparison of Tukey’s multiple statistical samples for tears from active primary and recurrent pterygium, and
healthy conjunctiva
Tukey’s multiple comparison test Mean diff. q Significant? Summary 95% CI of diff
Rec PtAct vs Pri Pt Act 0.07755 14.77 Yes *** 0.05875 to 0.09634
Rec PtAct vs Normal Conjun 0.1338 25.48 Yes *** 0.1150 to 0.1526
Pri Pt Act vs Normal Conjun 0.05627 10.71 Yes *** 0.03748 to 0.07506
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[11]. Hung et al., compared cystatin C expression in nor-
mal human oral mucosa and oral submucous fibrosis
(OSF). He demonstrated that OSF was expressed at
levels significantly higher than HCC in normal oral mu-
cosa at the RNA and protein level [21]. They
hypothesized that cystatin C had synergistic effects with
other antimicrobial substances such as lysozyme, lacto-
ferrin, and defensins, that make it more potent against
infectious pathogens. It contrast, it has been shown that
the balance between cystatin C and C1 cathepsin is of
major importance in the regulation of proteolytic activity
under normal physiological conditions, and for patho-
logical degradation that occurs in inflammatory diseases.
Our findings may be explained in the context of the pro-
tective role(s) of HCC; the protein may be trying to
maintain homeostatic redox at the anterior surface of
the eye.
Our ELISA and western blot results indicate low levels
of HCC in the tears and tissues of patients with a nor-
mal conjunctiva. The amount and concentration of HCC
were increased in the tears and tissues from patients
with pterygium, with the highest levels observed in
patients with active recurrent pterygium. Sharman et al.,
assess the concentration of HCC in gingival crevicular
fluid (GCF) and serum from patients with various peri-
odontal diseases, the mean HCC concentration in GCF
and serum was observed to be highest in patients with
periodontitis, and lowest in healthy individuals, they
suggested that HCC levels increased with disease pro-
gression to prevent further periodontal degeneration;
HCC levels then decrease after treatment to maintain
bone metabolic homeostasis [22]. Lertnawapan et al.,
found that concentrations of cystatin C were signifi-
cantly higher in the sera of patients with Systemic Lupus
Erythematosus (SLE) compared with controls. These
increased cystatin C levels correlated with increases in
erythrocyte sedimentation rate, Tumor Necrosis Factor-
alpha, and Interleukin 6, suggesting that cystatin C
concentrations in SLE may be affected by inflammatory
mechanisms [23]. Henskens et al., found that levels of
cystatin C were increased in the saliva of patients with
inflammatory periodontal disease in comparison with
healthy people [24]. Consider these findings and
combined with our results presented here, point to apossible role for HCC in fluids, as some sort of acute-
phase protein during inflammatory diseases.
We found that HCC was present to a great extent in
epithelial cells of pterygium samples. Underlying cells in
CT did not exhibit strong staining for HCC, suggesting
that the production of HCC is confined to epithelial
cells. This further indicates that pterygium does not in-
volve a clear inflammatory process. Based on these
findings, we can deduce that HCC acts as an epithelial
proliferatives stimulant, and at the same time as a
modulator of inflammation in underlying CT. This is
similar to what was outlined by Koroloenko et al., (2008)
[25] and Tavera et al., (1990) [26].Conclusion
Our study has established that HCC is expressed in nor-
mal conjunctiva and that this protein is up regulated in
proliferatives diseases of the ocular surface, such as
pterygium. This suggests that HCC may play a key role
(s) in the protection of a conjunctiva against aggressors,
and may regulate the inflammatory ocular response. The
molecular mechanism and potential of HCC as a prog-
nostic biomarker for activity or recurrence of pterygium
remains an area that requires further investigation.
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